We are a near clinical-stage biotechnology startup company specializing in

CRISPR-based precision genome editing medicine. We focus on delivering affordable

one-and-done in-body “DNA surgery” for genetic diseases with unmet needs. 

The Company's core areas of focus include novel Cas nuclease discovery and safe and efficient cargo delivery utilizing lipid nanoparticles (LNPs) and engineered protein delivery vehicles (PDVs).

Our visionary leaders bring decades of expertise in genome-editing therapy and business development, bringing innovation to affordable medical solutions. With deep scientific, clinical, business and strategic experience, they guide our mission to develop safe and precise CRISPR-based treatments.

We are building an expansive pipeline of cutting-edge in vivo genome-editing therapies that target ocular, metabolic, and rare diseases at their genetic roots. By editing genes directly in targeted organs and tissues in the body, we aim to cure diseases and improve quality of lives with safe, effective, and long-lasting medical solutions.